罗石Ross Keene

代表 / 资深顾问律师

上海 + 86.21.2201.8010

联系：

Share

罗石执业经验广泛，代理北美、欧洲、亚洲和澳洲客户经办在中国的跨境并购、外商直接投资、商业交易等项目。罗石来华工作已有十六年，代理客户经办的业务领域有金融服务、房地产、能源和资源、生命科学、技术、基础设施和制造业等。罗石还曾代理中国国有企业和私有制企业，经办其在澳洲和全球其他地区的海外收购和各类其他项目。

罗石的代表性交易包括就以下项目提供法律咨询建议：某主权财富基金作为财团的一成员以90.5亿澳元收购在澳洲证交所上市的Asciano Ltd；某中国国企就其在一家煤炭勘探上市公司的投资相关诉讼；许多外国投资商收购并处置其在中国的不良资产；许多全球房地产开发商和金融机构收购、经营并出售其在中国的一系列住宅、零售、工业和混合用途的房地产项目；以及中国和国际资源公司在非洲、澳洲和中国的各类项目。

罗石曾担任另一家国际律所上海代表处的首席代表，也曾在新加坡和澳大利亚墨尔本（逾五年）执业，代理客户经办在澳洲和亚洲的各类银行与金融、并购以及资源项目。

罗石在商洽和起草中英文交易文件方面拥有丰富的经验。

经验

  • Gaw Capital Partners enters strategic partnership with Sinar Primera in Indonesia data center developmentWorking with local Indonesian counsel, Jones Day advised Gaw Capital Partners regarding its entry into a strategic partnership with Sinar Primera, a leading Indonesian developer of new economy real estate, to develop an Internet Data Center at Nongsa Digital Park in Batam, Indonesia.
  • Gaw Capital Partners acquires Florentia Village Guangzhou Outlet MallJones Day advised Gaw Capital Partners in connection with the acquisition by a fund under Gaw’s management, alongside additional coinvestment partners, of Florentia Village Guangzhou, a designer outlet mall in Guangdong, China.
  • PTTGC acquires allnex from AdventJones Day advised PTT Global Chemical Public Company Limited in the €4 billion acquisition of allnex Holding GmbH from Advent International.
  • Helios Technologies completes acquisition of assets of JoyonwayJones Day advised Helios Technologies, Inc. in the acquisition of assets related to the electronic control systems and parts business of Shenzhen Joyonway Electronics & Technology Co., Ltd and its related entities (collectively “Joyonway”).
  • Axion BioSystems completes sale of company to Summa EquityJones Day advised Axion BioSystems, Inc., a leading provider of MEA and impedance technology for single-cell analysis, in its sale of the company to Summa Equity.
  • Major pharmaceutical company arbitrates claims arising out of Chinese investmentsJones Day is representing a major pharmaceutical company in a Hong Kong International Arbitration Centre arbitration arising out of representations and warranties given in respect of the client's investment in a Chinese drug development company whose senior officers and consultants were subsequently prosecuted in the United States for misappropriation of another pharmaceutical company's trade secrets.
  • U.S. design company conducts internal investigation into anonymous complaintsJones Day assisted a U.S. design company by conducting an internal investigation into anonymous allegations regarding the management and operations of the client's Chinese factory, including issues of conflicts-of-interest and corruption.
  • Greystar Asia Pacific forms Greystar China Multifamily Venture I LP with initial $450 million of commitmentsJones Day advised Greystar Asia Pacific Pte. Ltd. in connection with the formation of its first fund vehicle, Greystar China Multifamily Venture I LP, a Singapore-based fund that will acquire and develop multifamily real estate and real estate related assets in targeted cities in the Peoples Republic of China.
  • Lennox International sells refrigeration businesses in Australia, New Zealand, and Asia to Beijer Ref ABJones Day advised Lennox International Inc. in the sale of its refrigeration businesses in Australia, New Zealand, and Asia to Beijer Ref AB.
  • Glencore Singapore forms joint venture with Zhejiang Provincial PetroleumJones Day advised Glencore Singapore Pte. Ltd. on the formation of Zhejiang Petroleum Trading Co., Ltd., a joint venture with Zhejiang Provincial Petroleum Co., Ltd.
  • Pharmaceutical company successfully defends charge of commercial briberyA pharmaceutical company represented by Jones Day (in conjunction with local counsel) successfully challenged a charge of commercial bribery by a local branch of the Shanghai Administration of Industry and Commerce (AIC).
  • Newell Brands sells Winter Sports businesses to Kohlberg & Company for $240 millionJones Day advised Newell Brands Inc. (NYSE: NWL) in the sale of its Winter Sports businesses to private equity firm Kohlberg & Company for $240 million, subject to adjustment.
  • CIC Capital part of A$9.05 billion (US$6.75 billion) consortium for takeover of Asciano, one of the most complex transactions in Australia in recent times and largest deal in 2016Jones Day acted for CIC Capital Corporation on the A$9.05 billion (US$6.75 billion) takeover of rail and ports operator, Asciano, by a consortium including Brookfield, Qube Holdings, CPPIB, GIP, CIC Capital, GIC, Qatar Investment Authority, and bcIMC.
  • Wabtec acquires Gerken GroupJones Day advised Wabtec Corporation in its acquisition of Gerken Group SA, a leading manufacturer of specialty carbon and graphite products for rail and other industrial applications.
  • Ambrx and Hisun collaborate on development and commercialization of bispecifics for cancerJones Day represented Ambrx, Inc. in its collaboration with Zhejiang Hisun Pharmaceutical Company Ltd. for the development and commercialization of bispecifics based on Ambrx technology for the treatment of cancer.
    •

    January 2024 White Paper

    Employee Stock Plans: International Reporting Requirements

    2023年7月 白皮书

    工作中的人工智能：探讨劳动雇佣中自动化决策工具的法律环境

    January 2023 White Paper

    Employee Stock Plans: International Reporting Requirements

    January 2022 White Paper

    2021 Transactional Year in Review and 2022 Forecast

    2022年1月 白皮书

    2021年交易回顾及2022年展望

    December 2021 White Paper

    Employee Stock Plans: International Reporting Requirements

    May 2020 White Paper

    Construction Projects and Disputes: A Look Beyond the COVID-19 Lockdown, Part II

    May 2020 White Paper

    Construction Projects and Disputes: A Look Beyond the COVID-19 Lockdown

    2020年4月 法律评论

    新冠疫情和澳大利亚外商投资制度

    February 2020 Commentary

    China Further Opens its Market with New "Foreign Investment Law"
    查看全部观点

    • 2013年11月15日
      中国企业海外投资的风险管控研讨会

    发送前请注意

    *Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice